Mutations in the transmembrane receptor patched1 (ptc1) are responsible for the majority of basal cell carcinoma (BCC) cases. Many of these mutations, including ptc1-Q688X, result in premature truncation of the ptc1 protein. ptc1-Q688X has been identified in patients with both BCC and nevoid basal cell carcinoma syndrome, an inheritable disorder causing a predisposition to cancer susceptibility. Here we describe a mechanism by which ptc1-Q688X causes constitutive cellular signaling. Cells expressing ptc1-Q688X demonstrate an increase in cell cycle progression and induce cell transformation. The ptc1-Q688X mutant enhances Gli1 activity, a downstream reporter of sonic hedgehog (shh)-ptc1 signaling, independent of shh stimulation. In contrast to wild-type ptc1, ptc1-Q688X fails to associate with endogenous cyclin B1. Expression of nuclear-targeted cyclin B1 derivatives promotes Gli1-dependent transcription, which correlates temporally with cyclin B1-cdk1 kinase activity. Coexpression of wild-type ptc1 with a nuclear-targeted cyclin B1 derivative, mutated to mimic constitutive phosphorylation, dramatically decreases Gli1 activity. In addition, the coexpression of this constitutively nuclear cyclin B1 derivative with ptc1-Q688X substantially enhances foci formation. These studies therefore describe a molecular mechanism for the aberrant activity of ptc1-Q688X that includes the premature activation of the transcription factor Gli1. Oncogene (2005) 24, 902-915.
Introduction
Patched1 (ptc1), a 12-pass transmembrane protein, is the receptor for sonic hedgehog (shh). Morphogenetic signaling through the shh-ptc1 pathway is essential for embryonic development by mediating proliferation and cell fate determination (Hahn et al., 1996a; Johnson et al., 1996; Stone et al., 1996) . Insufficient signaling by shh-ptc1 during early development can result in disorders such as holoprosencephaly (HPE), a developmental defect of the forebrain and midface (Roessler et al., 1996; Nanni et al., 1999) . Conversely, constitutive activation of the shh-ptc1 pathway leads to nevoid basal cell carcinoma syndrome (NBCCS), an autosomal dominant disorder characterized by multiple developmental defects and cancer susceptibility, including basal cell carcinoma (BCC), one of the most common cancers in the US (Gorlin, 1995; Wicking and McGlinn, 2001 ). Many studies have demonstrated that mutations in ptc1, often leading to premature truncation, are responsible for a majority of NBCCS and BCC cases (Chidambaram et al., 1996; Gailani et al., 1996; Hahn et al., 1996b; Unden et al., 1996; Gailani and Bale, 1997) .
shh is a secreted morphogen that releases the inhibitory activity of ptc1 on smoothened (smo), a seven-pass transmembrane protein that functions as a signaling component of the shh-ptc1 pathway (Stone et al., 1996; Murone et al., 1999) . With shh bound, ptc1 allows for the activation of smo, which leads to the activation of the transcription factor Gli1 (Chen and Struhl, 1998) . Conversely, some smo missense mutations cause the constitutive activation of Gli1 even in the presence of overexpressed ptc1 (Xie et al., 1998; Murone et al., 1999; Taipale et al., 2000) . These oncogenic smo mutations are found in sporadic BCC tumors, suggesting that constitutive activation of smo is required for unchecked cell proliferation (Reifenberger et al., 1998; Xie et al., 1998; Lam et al., 1999) .
The synthesis, localization and destruction of cyclin proteins underlie the activation of cell cycle checkpoints (Hunter and Pines, 1994; Sherr, 1996) . The production of D-type cyclins is an essential yet limiting factor for G1-S progression (Quelle et al., 1993; Resnitzky et al., 1994) . Cyclin D1 is the regulatory subunit of the cdk4 and cdk6 holoenzyme complex, which phosphorylates and inactivates the tumor suppressor protein pRB allowing S-phase progression (Ewen et al., 1993; Matsushime et al., 1994) . M-phase promoting factor (MPF), which regulates the G2-M transition, consists of the regulatory subunit cyclin B1 and the catalytic kinase cdk1 (Nurse, 1990; Ducommun et al., 1991) . Expression of cyclin B1 alone can induce premature mitosis, due to the unregulated activity of cyclin B1-cdk1 kinase complexes (Hunter and Pines, 1994; Tam et al., 1995; Ghosh et al., 1996) . In addition, cyclin B1 is regulated by phosphorylation during G2 phase. Specifically, the cytoplasmic retention signal (CRS) domain of cyclin B1 is phosphorylated on four Ser residues, resulting in nuclear localization of MPF and access to critical nuclear substrates for G2-M progression (Li et al., 1995 (Li et al., , 1997 Borgne et al., 1999; Hagting et al., 1999) .
Recently, we demonstrated that cyclin B1 is a component of the shh-ptc1 pathway (Barnes et al., 2001) . Specifically, we found that the phosphorylated CRS domain of cyclin B1 bound to a region within the large intracellular loop of ptc1 (residues B704-750). We previously demonstrated that this ptc1-cyclin B1 association inhibited cell proliferation, indicating that ptc1 functions as a tumor suppressor at the G2-M transition in part by binding MPF. We also showed that cellular exposure to shh stimulated release of phosphorylated cyclin B1 from ptc1. This suggests that ptc1 may participate in cell cycle control by regulating the localization of cyclin B1-cdk1 complexes.
Here, we have examined a ptc1 mutation, reported in three individual cases, that is representative of a class of premature truncation mutations found in NBCCS/BCC patients. We demonstrate a proliferative advantage for 293T cells expressing the premature truncation mutant ptc1-Q688X compared to cells expressing wild-type ptc1. Mutant ptc1 expression can also transform NIH3T3 fibroblasts, suggesting that ptc1-Q688X promotes unregulated cell proliferation. We also show that the ptc1-Q688X mutant enhances Gli1 activity, independent of shh stimulation. The ptc1-Q688X mutant protein is defective in its ability to associate with endogenous cyclin B1, in contrast to wild-type ptc1. Lastly, through the use of Gli1-luciferase reporter assays, subcellular fractionation assays and immunofluorescence studies, we show that Gli1 transcriptional activity correlates temporally with MPF activity during prophase and that ptc1 has the ability to regulate cyclin B1-induced Gli1 activity.
Results

A common ptc1 mutation, ptc1-Q688X, fails to inhibit cell proliferation
To further investigate the role of ptc1 as a tumor suppressor, we examined a mutant of ptc1 found in patients with NBCCS and from a BCC tumor (Wicking et al., 1997a, b; Zhang et al., 2001) . This mutant, ptc1-Q688X, contains a C-T point mutation at nucleotide 2050, resulting in the mutation Gln-stop at residue 688 within the large intracellular loop of ptc1 ( Figure 1a ). Up to B86% of ptc1 mutations found in NBCCS cases result in premature truncation of the ptc1 gene product (Wicking et al., 1997b) , consistent with studies demonstrating the necessity for ptc1 function during early embryonic development. One function of ptc1 as a tumor suppressor is to inhibit cell proliferation. Cell proliferation assays were performed to compare mutant ptc1 with wild-type ptc1. We transfected 293T cells with empty vector (mock), Myc-tagged ptc1 or Myc-tagged ptc1-Q688X constructs and monitored proliferation over a period of 6 days post-transfection (Figure 1b ). 293T cells contain several components of the shh-ptc1 signaling pathway, including ptc1, smo and Gli1 proteins (data not shown). In addition, 293T cells are responsive to shh stimulation (Barnes et al., 2001; Thibert et al., 2003) . The overexpression of wild-type ptc1 prevents cell growth, consistent with an antiproliferative function. Mock-transfected cells serve as a control for unhindered cell cycle progression and cell growth. Cells transfected with ptc1-Q688X exhibit a level of proliferation comparable with mock-transfected cells. As a control for protein expression levels, cell lysates were immunoblotted to detect ptc1 and ptc1-Q688X proteins (Figure 1b, inset) .
The data from cell proliferation assays suggest that ptc1-Q688X lacks a suppressive effect on proliferation and is therefore unable to function as a tumor suppressor in this regard. To confirm that the expression of ptc1-Q688X fails to inhibit cell proliferation, we examined the mitotic phenotype of cells expressing ptc1 or ptc1-Q688X. The mitotic index of cells in prometaphase, metaphase and anaphase for the various cell populations is presented (Figure 1c ). This demonstrates that the overexpression of ptc1-Q688X leads to an increase in the mitotic index for these samples, which is comparable to mock-transfected cells. The mitotic index of cells expressing ptc1 is significantly decreased, reflecting fewer cells in M phase.
Phosphorylated histone proteins, including histone H3, serve as reliable markers for mitotic progression (Ito and Rubin, 1999) . Histone H3 is phosphorylated during prophase through anaphase of actively dividing cells. The number of ptc1-expressing cells positive for phospho-histone H3 expression is significantly decreased in relation to mock cells, reflecting fewer cells in M phase (Figure 1d ). The expression of ptc1-Q688X results in enhanced phospho-histone H3 expression (B3-fold) compared to cells expressing wild-type ptc1. These data suggest that the expression of ptc1-Q688X allows for mitotic progression and hence is unable to inhibit cell cycle progression.
ptc1-Q688X activity is not regulated by shh
The amino terminus of shh constitutes a biologically active fragment that is sufficient for interaction with ptc1 (Lee et al., 1994; Marigo et al., 1996) . The Nterminal shh product (shh-N) used in this study contains the first 197 amino acids of human shh and is sufficient to induce cell proliferation at the expense of ptc1 activity. We investigated the effect of shh addition on ptc1-Q688X-enhanced cell proliferation. We found that cellular exposure to shh-N increased the cell number in mock-and ptc1-transfected cells as expected (Figure 2a) . In contrast, ptc1-Q688X-expressing cells did not appear to be affected by shh-N exposure. The concentration of shh-N-conditioned media used in these experiments was sufficient for maximal stimulation as determined by the assessment of associated Gli1 activity (data not shown).
These results indicate that ptc1-Q688X-expressing cells are unresponsive to shh stimulation.
To examine the influence ptc1-Q688X may have on the regulation of Gli1 activity, we cotransfected NIH3T3 cells with a Gli1-luciferase reporter construct (Murone et al., 1999) and either empty Myc vector, wild-type ptc1 or ptc1-Q688X constructs ( Figure 2b ). As expected, wild-type ptc1 expression does not increase Gli1 activity compared to mock-transfected cells. In contrast, the expression of ptc1-Q688X enhances Gli1 activity about 3.5-fold over mock-and ptc1-transfected cells. As a control for shh-induced pathway activation, cotransfection into NIH3T3 cells with a vector encoding human shh-N was able to induce Gli1 reporter activity B3.5-fold for both mock-and ptc1-transfected cells. Cotransfection of shh-N with the ptc1-Q688X construct increased Gli1 activity modestly compared to cells expressing ptc1-Q688X alone. Consistent results were obtained with shh-N-conditioned media (data not shown). These results demonstrate that ectopic expression of ptc1-Q688X activates intracellular signaling events associated with the shh-ptc1 pathway independently of shh-ligand stimulation.
Another means by which ptc1 is regulated by shh association is through the turnover of ptc1 protein.
When shh binds to ptc1, it promotes the internalization and degradation of ptc1 protein (Denef et al., 2000; Incardona et al., 2002) . To investigate the turnover of ptc1, we employed a 293 tet-on inducible system, allowing induction of target protein expression by the addition of doxycycline (DOX). With the removal of DOX, induction of the target protein halts. We transfected empty vector (mock), Myc-tagged ptc1 and Myc-tagged ptc1-Q688X tet-on regulatory constructs into 293 inducible cells. After incubation with DOX, cells were chased with fresh media and harvested at the indicated times after DOX treatment7shh-N exposure. As demonstrated in Figure 2c , turnover of wild-type ptc1 protein increases when exposed to shh-N-conditioned media (upper panel). There is a substantial loss of ptc1 protein after shh-N exposure (upper panel, compare samples 3-6 with samples 9-12). In comparison, turnover of ptc1-Q688X increases slightly with exposure to shh-N (lower panel, compare samples 3-6 with samples 9-12). Quantitation of protein levels demonstrates that both wild-type ptc1 and ptc1-Q688X ptc1-Q688X-expressing NIH3T3 cells are susceptible to transformation ptc1-Q688X expression promotes cell proliferation. To investigate the oncogenic potential of the ptc1-Q688X mutation, we transfected NIH3T3 cells with wild-type or mutant ptc1 and examined them for morphological transformation. Cells transfected with wild-type ptc1 formed a uniform monolayer in culture, similar to mock-transfected cells. In contrast, ptc1-Q688X induced a transformed phenotype with focus formation. As compared to activated Neu (NeuNT), ptc1-Q688X displayed B23% transforming activity (Figure 3a) . Previous reports have demonstrated that other components of the shh-ptc1 signaling pathway can promote transformation. Specifically, two mutations found in smo can promote cell overgrowth and focus formation in a rat embryonic fibroblast cell line. These smo mutants result in B14% transforming activity of NRas (Xie et al., 1998) . Similarly, Gli1 overexpression enhances the formation of transformed, tumorigenic cells when expressed with the adenovirus E1A gene product (Ruppert et al., 1991) . Our findings support a role for ptc1-Q688X as an aberrant signaling component of the shh-ptc1 complex and provide direct evidence that mutated ptc1 functions as an oncogene.
Cyclin D1 is found overexpressed in several types of cancer (Hunter and Pines, 1994; Sherr, 1996) and it is believed that the unregulated expression of cyclin D1 protein commits a cell to enter S phase prematurely. The cellular response to shh exposure involves the transcription Figure 2 shh is unable to regulate ptc1-Q688X. (a) shh influence on cell proliferation in mock-, ptc1-and ptc1-Q688X-expressing 293T cells. Cells were transiently transfected with empty Myc vector, Myc-tagged ptc1 or Myc-tagged ptc1-Q688X constructs. shh-N protein was added to cell culture medium 48 h posttransfection with incubation for 24 h. (b) ptc1-Q688X constitutively activates the shh-ptc1 signaling pathway. NIH3T3 cells were cotransfected with empty Myc vector, Myc-ptc1 or Myc-ptc1-Q688X (7shh-N expression vector) and a Gli1-luciferase reporter construct. At 2 days after transfection, cell lysates were subjected to a luciferase assay. (c) Turnover of ptc1 and ptc1-Q688X proteins7shh-N exposure. Inducible 293 tet-on cells were transfected with pTRE empty vector (mock), pTRE-Myc-ptc1 or pTREMyc-ptc1-Q688X constructs. Protein expression was induced with DOX 24 h post-transfection. shh-N protein was added to the appropriate cell culture medium 48 h post-transfection. At the times indicated, samples were harvested and cell lysates analysed by SDS-PAGE and immunoblotted for Myc-tagged proteins. The relative protein turnover rates of ptc1 and ptc1-Q688X up to 24 h after induction are shown in the upper and lower panels, respectively (samples 2-6). The relative protein turnover rates of ptc1 exposed to shh-N and ptc1-Q688X exposed to shh-N up to 24 h after induction are shown in the upper and lower panels, respectively (samples 8-12). Samples 1 and 7 represent mocktransfected samples incubated7shh-N. b-Tubulin immunoblots serve as controls for protein loading. (d) Quantitation of ptc1 (upper panel) and ptc1-Q688X turnover (lower panel). The results shown are the mean values (7s.e.m.) of three independent experiments, expressed as the percentage of ptc1 or ptc1-Q688X protein levels compared to controls of cyclin D1 (Kenney and Rowitch, 2000; DumanScheel et al., 2002) . To investigate the role of cyclin D1 in the aberrant cell growth caused by the expression of ptc1-Q688X, we transfected empty Myc vector (mock), Myc-tagged ptc1 or Myc-tagged ptc1-Q688X into NTERA-2 cells. NTERA-2 cells are an embryonal teratogenic cell line that tightly regulates the expression of both cyclin D1 and ptc1 genes (Satoh and Kuroda, 2000; Freemantle et al., 2002) . With the expression of wild-type ptc1, cyclin D1 protein levels are downregulated as expected ( Figure 3b , upper panel, sample 2). In contrast, ptc1-Q688X-transfected cells do not downregulate cyclin D1 protein to the extent of wildtype ptc1 (Figure 3b , upper panel, sample 3). The level of cyclin D1 protein detected in sample 3 closely mirrors the level of cyclin D1 protein synthesized in mocktransfected cells (Figure 3b , upper panel, sample 1). These results demonstrate that the ptc1-Q688X mutant fails to properly regulate expression of cyclin D1.
Lack of association between ptc1-Q688X and cyclin B1
During G2 phase, MPF becomes activated and then enters the nucleus to induce mitotic events that commit a cell to progress through M phase. The phosphorylation of cyclin B1 occurs prior to MPF nuclear entry. Previously, we demonstrated that ptc1 associates with Figure 4 ptc1-Q688X is unable to associate with cyclin B1. 293T cells were transiently transfected with empty Myc vector, Myctagged ptc1 or Myc-tagged ptc1-Q688X constructs. Cell lysates were immunoprecipitated with cyclin B1 antisera to examine ptc1 association by 7.5% SDS-PAGE and immunoblot analysis. The upper panel shows associated Myc-tagged ptc1 protein in cyclin B1 immunoprecipitates (sample 2). The center panel demonstrates equal expression of endogenous cyclin B1 proteins in immunoprecipitate samples (samples 1-3). As a control for ptc1 protein expression, the lower panel demonstrates expression of Myc-tagged ptc1 proteins (samples 2 and 3) a mutant of cyclin B1 that mimics constitutive phosphorylation; this interaction blocks cell cycle progression by inhibiting the nuclear translocation of MPF. Furthermore, shh-N exposure promoted cell proliferation at the expense of the ptc1-cyclin B1 interaction, resulting in nuclear localization of MPF (Barnes et al., 2001) . To determine if ptc1-Q688X associates with endogenous cyclin B1, we expressed Myc-tagged ptc1 or Myc-tagged ptc1-Q688X proteins in 293T cells and performed co-immunoprecipitation experiments with cyclin B1 antisera. We found that endogenous cyclin B1 immunoprecipitates do not contain associated ptc1-Q688X protein (Figure 4 , upper panel, sample 3); in contrast, wild-type ptc1 associates with endogenous cyclin B1 (Figure 4 , upper panel, sample 2). As controls for protein expression, the center panel demonstrates recovery of cyclin B1 in cyclin B1 immunoprecipitates and the lower panel demonstrates the expression of Myc-ptc1 proteins in cell lysates. These results indicate that the prematurely truncated mutant, ptc1-Q688X, is unable to associate with cyclin B1.
Expression of constitutively nuclear cyclin B1 constructs enhances Gli1 activity
The ptc1-Q688X mutant is unable to associate with cyclin B1 and ptc1-Q688X expression induces Gli1 activity, implicating a possible link between cyclin B1 and the regulation of Gli1. To examine this further, we cotransfected NIH3T3 cells with a Gli1-luciferase reporter construct and empty Myc vector (mock), hs-E or VSV-G-tagged NLS-B1
hs-A and a Gli1-luciferase reporter construct. (c) Gli1 activity is prophase dependent. NIH3T3 cells were cotransfected with a Gli1-luciferase reporter construct and empty Myc vector construct (samples 1-7) or shh-N expression vector (sample 8). At 2 days after transfection, cells were treated with 0.33 mM NOC for increasing time periods (sample 1, 0 min; sample 2, 5 min; sample 3, 15 min; sample 4, 30 min; sample 5, 1 h; sample 6, 2.5 h; sample 7, 5 h), and cell lysates were then subjected to a luciferase assay. Sample 8 serves as a positive control for shh-N-induced Gli1 reporter activity. Line graph shows the mitotic index of prophase cells from each sample described above. (d) Gli1 activity is a specific event during prophase. NIH3T3 cells were transfected with a Gli1-luciferase reporter construct (samples 1-10). At 1 day after transfection, cells were refed with 0.2% calf serum medium. At 30 h post-transfection, cells were incubated with 1 mM HU for 18 h, except for the cells represented in sample 1, which were not exposed to HU. Cells were then released into 10% calf serum medium and harvested at the indicated time points after HU release: sample 1, 0 h (no HU); sample 2, 0 h; sample 3, 1 h; sample 4, 2 h; sample 5, 3.5 h; sample 6, 4.5 h; sample 7, 5.5 h; sample 8, 6.5 h; sample 9, 7.5 h; sample 10, 8.5 h. Cell lysates were then subjected to a luciferase assay. Line graph shows the mitotic index of prophase cells from each sample described activating derivatives of Xenopus cyclin B1, wild-type ptc1 or ptc1-Q688X constructs. The cyclin B1 derivatives used in this study contain the four Ser phosphorylation sites in the CRS domain mutated to Glu or to Ala to mimic phosphorylated or unphosphorylated cyclin B1, respectively. In addition, each cyclin B1 derivative contained an appended nuclear localization signal (NLS) to target each protein to the nucleus (NLS-B1 E and NLS-B1 A ). ptc1 expression leads to no increase in Gli1 activity (Figure 5a ). In contrast, ptc1-Q688X expression induces Gli1 activity to about threefold over mock-transfected cells. Surprisingly, the expression of NLS-B1 E or NLS-B1 A enhances Gli1 activity to about five-and fourfold, respectively, over mock-and ptc1-transfected cells. Cotransfection of NLS-B1 E with ptc1 demonstrates that Gli1 activity is substantially downregulated. These results demonstrate that expression of NLS-B1 E activates intracellular signaling associated with the shh-ptc1 pathway and that ptc1 coexpression inhibits NLS-B1 E -induced Gli1 reporter activity. Previously, we demonstrated that ptc1 binds to phosphorylated cyclin B1, but fails to bind unphosphorylated cyclin B1 (Barnes et al., 2001) . To examine if unphosphorylated cyclin B1 protein has an effect on Gli1-luciferase reporter activity in the presence of wildtype ptc1, we cotransfected NLS-B1
A and ptc1 constructs with the Gli1-luciferase reporter. The cotransfection of NLS-B1
A with wild-type ptc1 shows that Gli1 remains stimulated (Figure 5a ). To confirm that the cyclin B1-induced Gli1 stimulation observed is not a species-specific effect, we constructed human cyclin B1 derivatives for use in the Gli1 reporter assays (NLS-B1 hs-A and NLS-B1
hs-E ). These nuclear-targeted cyclin B1 derivatives contain the five Ser phosphorylation sites in the human CRS domain (S116, S126, S128, S133 and S147) mutated to Ala or Glu, to mimic phosphorylation states of cyclin B1 (Hagting et al., 1999) . Xenopus cyclin B1 contains four regulatory phosphoserine sites within the CRS (Li et al., 1995) . The expression of NLS-B1
hs-E enhances Gli1 activity to about sixfold over mocktransfected cells (Figure 5b ). The cotransfection of NLS-B1
hs-E with wild-type ptc1 demonstrates that Gli1 activity is downregulated. These results demonstrate that expression of the human construct NLS-B1
hs-E activates intracellular signaling events associated with the shh-ptc1 pathway, consistent with Xenopus NLS-B1 E (Figure 5a ). Figure 5b also demonstrates that NLS-B1 hs-A expression substantially upregulates Gli1 reporter activity to 16-fold over mock-transfected cells. The mechanism of NLS-B1 hs-A -enhanced Gli1 activity is unclear at this time, although it may be due to mutation of Ser116, absent at the homologous position within the Xenopus NLS-B1
A construct. Yet similar to Xenopus NLS-B1
A , ptc1 coexpression is unable to abolish NLS-B1 hs-A -induced Gli1 activity.
Gli1 transcriptional activity occurs during prophase
The localization of MPF in the nucleus promotes Mphase progression. Therefore, the link between cyclin B1 nuclear localization and Gli1 activity may be of a temporal nature. To examine if Gli1 activity is M-phase specific, we transfected NIH3T3 cells with a Gli1-luciferase reporter construct and then treated each sample with nocodazole (NOC). NOC is a microtubule inhibitor that depolymerizes microtubules involved in the completion of prometaphase, hence cells exposed to low doses of NOC accumulate first in prophase and then enter prometaphase where they remain arrested until released (Jha et al., 1994; Cimini et al., 1998; Rieder and Cole, 2000) . Cell samples were treated with a low dose of NOC (0.33 mM) for various times and then harvested. Early exposure to NOC produces an enrichment of cells in prophase as determined by mitotic index and phospho-histone H3 expression (Figure 5c , line graph, samples 2-4). Incubation with NOC for longer times produces more cells in prometaphase, which eventually become prometaphase-arrested (Figure 5c , line graph, samples 5-7). Gli1-luciferase assays demonstrate that early exposure to NOC corresponds to an increase in Gli1-luciferase activity (Figure 5c , bar graph, samples 2-4). As cells progress through M phase and enter prometaphase, there is an associated decrease in Gli1 activity (Figure 5c , bar graph, samples 5-7). As a control for shh-N-induced Gli1 reporter activity, the expression of shh-N protein upregulates Gli1 activity to about threefold, as shown in this study (Figure 5c , bar graph, sample 8). And the mitotic index of shh-Ntransfected cells in prophase is B4.5-fold over mock (Figure 5c , line graph, sample 8). These results demonstrate that NOC treatment of cells can indirectly activate intracellular signaling events associated with Gli1 reporter activity, and that Gli1 transcriptional activity may be prophase dependent.
To confirm that the cellular treatment with NOC increases Gli1 reporter activity due to the enhancement of mitotic cell cycle phase populations and not due to other NOC-induced cellular effects, NIH3T3 cells transfected with the Gli1 reporter construct were synchronized with an alternative method to accumulate cells in prophase. First, cell samples were treated with 1 mM of hydroxyurea (HU) for 18 h to accumulate cells in S phase. Following treatment, cell samples were released and harvested at the indicated time points. There is an enrichment of cells in prophase as determined by mitotic index and phospho-histone H3 expression by 4.5 h after release from HU (Figure 5d , line graph, sample 6), indicating the beginning of M phase. Gli1-luciferase assays demonstrate that there is a substantial increase in Gli1-luciferase activity during prophase (Figure 5d , bar graph, samples 7 and 8). As cells progress through M phase, there is an associated decrease in Gli1 activity (Figure 5d , bar graph, samples 9 and 10). Interestingly, samples 9 and 10 demonstrate a substantial enrichment of cells in prophase, indicating that these cells are maintaining synchronization as they progress through M phase (Figure 5d , line graph). These results not only confirm the NOC synchronization assays but also demonstrate that Gli1 transcriptional activity is cell cycle dependent, and suggest that Gli1-associated activity is an early prophase event.
Gli1 nuclear localization coincides with cyclin B1 activity during prophase
To further examine the link between cyclin B1 nuclear localization and Gli1 activity, we treated NIH3T3 cells with NOC for various time periods, harvested and then subjected to nuclear fractionation procedures. Figure 6A demonstrates that by mid-prophase endogenous phosphorylated cyclin B1 enters the nucleus (upper and middle panels, samples 5-7). The mitotic indices of cell samples treated with NOC are shown in Figure 6B , demonstrating that a temporal increase in NOC cellular exposure corresponds to an enrichment of cells in prophase (samples 2-6). The incubation of cells with NOC for longer time periods produces more cells in prometaphase and by 5 h the number of prometaphase cells surpasses the number of prophase cells ( Figure 6B , sample 7). Flow cytometry analysis of these samples further demonstrates a corresponding increase in Mphase entry with increasing exposure to NOC (data not shown). As a control for nuclei recovery, the lower panels demonstrate the expression of lamin protein in the nuclear fractions of cell lysates ( Figure 6A, samples  1-7) . The cell lysates from the cytoplasmic fractions did When examined for the nuclear expression of Gli1 protein by indirect immunofluorescence, we found that the nuclear localization of Gli1 occurs during prophase ( Figure 6C, panel a) . Furthermore, Gli1 nuclear expression coincides temporally with the expression of phosphorylated cyclin B1 in the nucleus (Figure 6A and C). As a control for the specificity of NOC-induced nuclear localization, NIH3T3 cells were transfected with a GFP expression vector and then treated with or without NOC. In the presence of NOC, GFP protein did not alter its subcellular distribution (data not shown). Quantitation of Gli1 nuclear localization in NOCsynchronized samples demonstrates that cyclin B1 nuclear entry and Gli1 nuclear transport occur in prophase ( Figure 6A , sample 5, and Figure 6D , samples 5 and 6). These results suggest that cyclin B1 mitotic activity promotes Gli1 transcriptional activity.
NLS-B1 E enhances focus formation in cells expressing ptc1-Q688X
Expression of ptc1-Q688X promotes aberrant cell growth (Figure 3a) . Expression of NLS-B1 E promotes cell proliferation and Gli1 transcriptional activity. Therefore, to investigate the oncogenic potential of the ptc1-Q688X mutation coexpressed with an active form of cyclin B1 (NLS-B1 E ), we cotransfected NIH3T3 cells with NLS-B1 E and wild-type or mutant ptc1 and assessed for focal cell overgrowth. Cells transfected with wild-type ptc1 failed to form foci (Figure 7a and b) . In contrast, expression of ptc1-Q688X induced a transformed phenotype with 28% transforming activity (Figure 7a ). We found that in all cases examined, the coexpression of NLS-B1 E enhanced foci formation. Foci formation was substantially enhanced to 93% transforming activity with the coexpression of ptc1-Q688X and NLS-B1 E . In addition, we exposed mock-, ptc1-and ptc1-Q688X-transfected samples to shh-N-conditioned media to determine the effect shh exposure may have on cell transformation. We found that in all cases, shh-N cellular exposure enhanced foci formation compared to untreated samples (Figure 7a ). These results demonstrate that shh-N overexpression can induce cell transformation, and that the mislocalization of MPF may contribute to aberrant activation of the shh-ptc1 signaling pathway.
Discussion
Constitutive activation of the shh-ptc1 pathway leads to NBCCS, a syndrome complicated with several developmental defects (Gorlin, 1995) . NBCCS also predisposes patients to a variety of the most common cancerous afflictions, such as BCC, medulloblastoma and rhabdomyosarcoma (Gorlin, 1995; Cohen, 1999) . Disruption of ptc1 or smo, or deregulation of the transcription factor Gli1, may represent the critical event in the development of BCC. In addition, inactivation of shh-ptc1 signaling may result in developmental defects, such as holoprosencephaly (Roessler et al., 1996; Cohen, 1999) . Therefore, proper shh-ptc1 signaling is crucial for important developmental processes as well as the normal regulation of cell cycle progression.
We chose to address this issue by examining a ptc1 point mutation identified in patients with either NBCCS or BCC. The C2050T point mutation results in a Glnstop substitution within the large intracellular loop of the ptc1 protein. We previously determined that cyclin B1 binds to the latter portion of the large intracellular loop of ptc1, interacting with residues B704-750 (Barnes et al., 2001) . Most of the mutations identified in patients with NBCCS or NBCCS-associated cancers result in premature truncation of the ptc1 protein with a significant number of mutations residing within residues 663-694, indicating a putative 'mutational hot spot'. E as indicated. At 2 days after transfection, shh-N-conditioned medium was added to the appropriate samples. (b) Selected plates of NIH3T3 focus forming assays. After 14 days of incubation, cells were fixed with methanol and stained with Giemsa to visualize foci One of the more common ptc1 mutations found within this region is the Gln688X (or Q688X) mutation (Figure 1a) , which is found not only in NBCCS but also in sporadic BCC (Wicking et al., 1997a, b; Zhang et al., 2001 ).
In the current study, we demonstrate that expression of the ptc1-Q688X mutant exhibits unregulated activity by failing to inhibit cell proliferation in a ligandindependent manner (Figures 1b and 2a) . ptc1-Q688X promotes mitotic progression as determined by mitotic index assays and phospho-histone H3 expression (Figure 1c and d) . Furthermore, ptc1-Q688X promotes aberrant cell growth, as assayed by focus formation assays, indicating that expression of ptc1-Q688X alone can serve as a proto-oncogene (Figure 3a) . The aberrant cell cycle progression associated with ptc1-Q688X expression is also reflected in upregulation of cyclin D1 (Figure 3b ). Cyclin D1 expression has been found to occur in several types of cancer, and has been shown to be upregulated in response to shh cellular exposure.
shh binds to the two large extracellular loops of ptc1 to initiate the intracellular signaling cascade associated with the shh-ptc1 pathway. In this manner, the cell cycle regulatory and tumor suppressor activities of ptc1 are regulated by external developmental cues. Two consequences of shh binding are stimulation of cellular proliferation and upregulation of Gli1 activity (Dahmane et al., 1997; Green et al., 1998; Liu et al., 1998; Kenney and Rowitch, 2000; Barnes et al., 2001; Lowrey et al., 2002) . shh-N has been shown to induce Gli1 transcriptional activity (from two-to sixfold over mock) using a Gli1-luciferase reporter system (Murone et al., 1999; Zeng et al., 2001; Taipale et al., 2002) . Moreover, expression of oncogenic forms of smo proteins independent of shh-N cellular exposure enhances Gli1-luciferase reporter activity about 6-8-fold over mock-transfected cells (Murone et al., 1999) . The ptc1-Q688X mutant exhibits constitutive Gli1 transcriptional activity (approximately fourfold) and an increase in cell proliferation independent of shh-ligand stimulation (Figure 2a  and b) .
Mutant ptc1 protein does not turn over efficiently with shh-N cellular exposure (Figure 2c ). Previously, two other studies have examined the molecular basis of several human ptc1 mutants identified from NBCCS/ BCC patients (Bailey et al., 2002 (Bailey et al., , 2003 . Results from these studies demonstrated that ptc1 mutants unable to mature have reduced protein stability and are unable to inhibit endogenous ptc1 promoter activity. It appears then that ptc1 mutations that alter single amino acids may retain residual ptc1 activity and be associated with milder clinical outcomes, as compared to ptc1 truncation mutations that may correlate with more severe phenotypes associated with NBCCS/BCC.
Previously, we demonstrated that a form of cyclin B1 present only during the G2-M transition bound to ptc1 (Barnes et al., 2001) . In this report, we demonstrate that cyclin B1 is unable to associate with ptc1-Q688X (Figure 4 ). In addition, overexpression of nucleartargeted forms of cyclin B1 leads to enhanced Gli1-luciferase reporter activity (Figure 5a and b) . Only NLS-B1 E -induced Gli1 reporter activity is inhibited by the coexpression of ptc1. In contrast, NLS-B1 A -related Gli1 activity remains unaffected. Therefore, the nuclear localization and/or nuclear accumulation of cyclin B1 protein may precede Gli1 activation. The activation of Gli1 represents an important cellular response to signaling by the shh-ptc1 pathway. We show here that cellular exposure to shh promotes Gli1 transcriptional activity during prophase (Figure 5c ). In addition, using cell synchronization and subcellular fractionation assays, we show that cyclin B1 enters the nucleus and promotes Gli1 activity during prophase (Figures 5c, d  and 6A-D) . Therefore, the link between cyclin B1 nuclear localization and Gli1 activity may be temporal in nature.
The end results of the ptc1-Q688X mutation on ptc1 activity vary from loss-of-function to oncogenic effects. Cell proliferation assays, cyclin D1 protein expression and cyclin B1 association represent pathways that ptc1-Q688X fails to inhibit, reflecting loss-of-function effects (Figures 1b-d, 2a, 3b and 4) . ptc1-Q688X is a more common mutation associated with both BCC and NBCCS (Wicking et al., 1997a, b; Zhang et al., 2001) . The loss of ptc1 function has been shown to underlie the developmental defects associated with NBCCS (Hahn et al., 1996a; Johnson et al., 1996; Wicking et al., 1997b) . Therefore, the loss-of-function effects associated with ptc1-Q688X may reflect signaling pathways primarily involved in embryonic development. The signaling pathways stimulated by the constitutive activity of ptc1-Q688X may contribute to aberrant cell growth. In fact, BCCs are associated with the hyperactivation of Gli1 (Dahmane et al., 1997; Green et al., 1998) . Similarly, the expression of ptc1-Q688X induces the activation of Gli1 (Figures 2b, 5a and b) . Studies have shown that overexpression of either Gli1 or oncogenic forms of smo, found in patients with BCC, results in cell transformation (Ruppert et al., 1991; Xie et al., 1998) . ptc1-Q688X also induces focus formation (Figures 3a, 7a and b) , indicating that the expression of mutant ptc1 activates pathways that contribute to oncogenesis.
The results presented here describe uncontrolled cell proliferation and constitutive intracellular signaling resulting from a prematurely truncated ptc1 mutant. Other point mutants or truncation mutants of ptc1 found in BCC/NBCCS patients may affect regulation of one or more of the pathways examined here. Further investigation into the signaling pathways activated by specific mutants will contribute to our understanding of NBCCS and BCC.
Materials and methods
Expression constructs
To construct ptc1-Q688X, oligonucleotides encoding the Gln688X mutation were incorporated in-frame into the Myctagged ptc1 plasmid using BlpI and SnaBI restriction sites. To construct the human cyclin B1 derivatives with an appended NLS (NLS-B1
hs-A and NLS-B1
hs-E ), oligonucleotides encoding a SacII site were incorporated in-frame into the pCMX-Cyclin B1-GFP plasmids by use of EcoRI and BamHI sites. Human cyclin B1 derivatives (pCMX-Cyclin B1-GFP 5XA and pCMX-Cyclin B1-GFP 5XE) were a kind gift of Dr Anja Hagting. The intermediate products, pCMX-Cyclin B1 5XA and pCMX-Cyclin B1 5XE, were digested with NcoI and SacII to isolate each cyclin B1 gene. Oligonucleotides encoding the NLS of Xenopus nucleoplasmin were then incorporated inframe into each cyclin B1 gene and the pcDNA3-VSV-Gtagged vector using HindIII, NcoI and SacII sites. Cyclin B1 (NLS-B1
A and NLS-B1 E ), ptc1 and shh-N derivatives were described previously (Li et al., 1997; Barnes et al., 2001) . Final constructs were confirmed by DNA sequencing. The 9 Â Gli1-luciferase reporter construct contains nine copies of the Gli1 protein-binding site (BS) of the mouse Hepatocyte Nuclear Factor-3b (HNF-3b) minimal floor plate enhancer upstream of the herpes simplex virus (HSV) thymidine kinase (TK) minimal promoter and the luciferase gene (Murone et al., 1999) . The Gli1 BS of the HNF-3b floor plate enhancer acts as a shh responsive element (Sasaki et al., 1997) .
Cell proliferation assays
Human embryonic kidney 293T cells were seeded at a density of 1.0 Â 10 5 cells/plate (60 mm) and transfected by calcium phosphate precipitation with 5.0 mg of empty Myc vector (pCS3 þ MT), Myc-tagged ptc1 or Myc-tagged ptc1-Q688X DNA. Cells were counted every 48 h after transfection by Coulter counter. Cells from 48 h post-transfection were harvested in 1% NP-40 buffer (Barnes et al., 2001 ) and cell lysate samples were analysed by 7.5% SDS-PAGE for protein expression with a 1 : 1000 dilution of c-Myc 9E10 antisera (Santa Cruz). 
Mitotic marker assays
293T cells were plated onto collagen-coated coverslips (Becton Dickinson) and transfected with 10 mg of the appropriate construct as described for the cell proliferation assays. NIH3T3 cells were plated onto glass coverslips and transfected as described for the Gli1-luciferase reporter assays. At 48 h after transfection, cells were fixed with 3% paraformaldehyde and permeabilized with blocking solution (0.1% Triton X-100, 0.2 M glycine and 2.5% fetal bovine serum (FBS) in PBS). Nuclei were stained with 50 ng/ml of Hoechst 33342 dye (Sigma). Phospho-histone H3 protein was visualized by use of a 1 : 200 dilution of phospho-H3 antisera (Upstate) with a 1 : 500 dilution of rhodamine-conjugated anti-rabbit antisera (ICN-Cappel). For the 293T cells, a minimum of 1000 cells were counted per sample from three independent transfections, presented as fold-increase in cells expressing a mitotic phenotype or phosphorylated histone H3 (mean values7s.e.m.), relative to ptc1-expressing cells (standard set at 1).
Gli1-luciferase reporter assays
NIH3T3 cells were plated at 2.0 Â 10 5 cells/plate (60 mm) 24 h before transfection. Cells were cotransfected with 4 mg of 9Â Gli1-luciferase reporter construct (Genentech Inc.), 2 mg of the appropriate ptc1 construct (ptc1 or ptc1-Q688X), 1 mg of shh-N construct and/or 1 mg of the appropriate cyclin B1 construct (NLS-B1
hs-A or NLS-B1 hs-E ). Mock-transfected cells were cotransfected with 4 mg of 9 Â Gli1-luciferase reporter construct and 2 mg of empty Myc vector (pCS3 þ MT) and/or 1 mg of shh-N construct. At 24 h after transfection, cells were refed with medium containing 0.2% calf serum for an additional 24 h. Luciferase assays were performed with the luciferase assay system (Promega). Transfection efficiencies were monitored by indirect immunofluorescence and determined to be equal. Each assay was performed in duplicate and the results shown represent the mean values (7s.e.m.) of three independent experiments, presented as the relative foldincrease (relative light units (RLU)) over mock-expressing cells.
Pulse-chase assays
Inducible 293 tet-on cells (BD Biosciences) stably expressing the rtTA plasmid by 100 mg/ml of G418 selection were seeded at 1 Â 10 5 cells/plate (60 mm) 24 h before transfection. Cells were transfected with 2.5 mg of the pTRE derivatives: pTRE2hyg (mock), pTRE-Myc-ptc1 or pTRE-Myc-ptc1-Q688X. At 24 h post-transfection, protein expression was induced with 5 mg/ml DOX. At 24 h after induction, cell samples were rinsed and refed with 10% FBS (chase media) with or without shh-N-conditioned media. After induction and shh exposure, cells were harvested at 0, 3, 6, 9 and 24 h. Cell lysates were standardized by Bradford assay, analysed by 7.5 or 10% SDS-PAGE and immunoblotted with a 1 : 1000 dilution of c-Myc 9E10 antisera (Santa Cruz) and a 1 : 250 dilution of b-tubulin H-235 antisera (Santa Cruz) as indicated. The half-lives of ptc1 and ptc1-Q688X proteins were quantitated through the use of NIH Image software. The results shown are the mean values (7s.e.m.) of three independent experiments, expressed as the percentage of ptc1 or ptc1-Q688X protein levels compared to each respective control (0 time point). In each case, t 1/2 was determined as the time (h) after the addition of chase media (10% FBS 7shh-N-conditioned media) required to achieve 50% of relative protein levels as compared to the 0 time point (control).
Focus assays
NIH3T3 cells were plated at 2.0 Â 10 5 cells/plate (60 mm) 24 h before transfection. Cells were transfected with 10 mg DNA for the ptc1 derivatives (ptc1 or ptc1-Q688X), 2.5 mg DNA for NLS-B1 E or 5.0 mg DNA for NeuNT. NeuNT-and ptc1-transfected samples were cotransfected with 25 and 50 ng of pRSVneo, respectively. At 24 h after transfection, cells were refed with medium containing 10% calf serum. Cells were split 1 : 12 onto 100 mm plates after 24 h. At this time, shh-Nconditioned medium was added to the appropriate samples. Foci were counted after 12-14 days after methanol fixation and staining with 0.4% Giemsa solution. Transfection efficiencies were determined by G418-resistant colonies on parallel plates after 8 days. The results shown represent foci formed relative to individual transfection efficiencies, shown as the mean (7s.e.m.) of at least three separate experiments. Oncogenic Neu (NeuNT), activated by the Val664Glu mutation, served as the positive control (set at 100%) (Bell et al., 2000) . The transforming activities of ptc1 and ptc1-Q688X constructs are presented as percentages with respect to the positive control.
Co-immunoprecipitations
At 2 days after transfection with empty Myc vector, Myctagged ptc1 or Myc-tagged ptc1-Q688X constructs, 293T cells were harvested in PBS and then lysed in 1% NP-40 buffer. Protein content was standardized by Bradford assay. Lysates were incubated with 1 mg of cyclin B1 M-20 antisera (Santa Cruz). The immunoprecipitated samples represent 1/2 of total cell lysates and the lysate samples represent 1/30 of total cell lysates. Samples were analysed by 7.5% SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted for cyclin B1 and Myc-tagged ptc1 proteins with a 1 : 1000 dilution of cyclin B1 GNS1 antisera (Santa Cruz) and a 1 : 1000 dilution of c-Myc 9E10 antisera (Santa Cruz), respectively.
Western immunoblots
At 2 days after transfection with empty Myc vector, Myctagged ptc1 or Myc-tagged ptc1-Q688X constructs, NTERA-2 cells were rinsed in PBS and then lysed in 1% NP-40 buffer. Protein content was standardized by Bradford assay. Lysate samples were analysed by 10% SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted for cyclin D1, btubulin and Myc-tagged ptc1 proteins with a 1 : 1000 dilution of cyclin D1 M-20 antisera (Santa Cruz), a 1:250 dilution of btubulin H-235 antisera (Santa Cruz) and a 1 : 1000 dilution of c-Myc 9E10 antisera (Santa Cruz), respectively. All Westerns were probed with the appropriate HRP-conjugated secondary antisera (Amersham), mouse or rabbit, at a dilution of 1 : 2500 with proteins detected by ECL (Amersham).
Nocodazole treatment
NIH3T3 cells were plated at a density of 2.0 Â 10 5 cells/plate (60 mm). After incubation for 24 h, cells were cotransfected by calcium phosphate precipitation with 4 mg of 9Â Gli1-luciferase reporter construct and 4 mg of empty Myc vector or with 4 mg of 9 Â Gli1-luciferase reporter construct and 1 mg of shh-N construct. At 24 h post-transfection, cells were refed with medium containing 0.2% calf serum. After 24 h, NOC (Sigma) was added to NOC-treated samples at a final concentration of 0.33 mM. Cells were harvested at 0, 5 min, 15 min, 30 min, 1 h, 2.5 h and 5 h of NOC treatment. Luciferase assays were performed with the luciferase assay system (Promega). Each assay was performed in duplicate. The results shown represent the mean values (7s.e.m.) from three separate experiments. Coverslips from each experiment were examined to determine the mitotic index of each sample as described above. A minimum of 200 cells were counted per sample from three independent transfections, presented as the fold-increase in cells expressing phosphorylated histone H3 (prophase only) relative to sample 1 (standard set at 1).
Hydroxyurea treatment
Synchronized samples were prepared as described elsewhere with slight modification (Tobey et al., 1990) . Briefly, NIH3T3 cells were plated at a density of 2.0 Â 10 5 cells/plate (60 mm). After incubation for 24 h, cells were transfected by calcium phosphate precipitation with 4 mg of 9Â Gli1-luciferase reporter construct. At 24 h post-transfection, cells were refed with medium containing 0.2% calf serum. After 6 h, cells were incubated with a final concentration of 1 mM HU for 18 h to synchronize cells in S phase. Sample 1 represents cells not treated with HU. Cells were then rinsed 2 Â with 10% calf serum medium and incubated in 10% calf serum medium until harvested at the following time points: 0, 1, 2, 3.5, 4.5, 5.5, 6.5, 7.5 and 8.5 h. Luciferase assays were performed as described above. Each assay was performed in duplicate. The results shown represent the mean values (7s.e.m.) from three separate experiments. Coverslips from each experiment were examined to determine the mitotic index of each sample as described above. A minimum of 200 cells were counted per sample from two independent transfections, presented as the fold-increase in cells expressing phosphorylated histone H3 (prophase only) relative to sample 1 (standard set at 1).
Nuclear fractionation assays
NIH3T3 cells were plated at a density of 2.0 Â 10 5 cells/plate (60 mm). After incubation for 48 h, cells were starved with 0.2% calf serum for 42 h. Cells were then refed with 10% calf serum and treated with 0.33 mM NOC for the time periods indicated (0, 5 min, 15 min, 30 min, 1 h, 2.5 h and 5 h). Fractionated samples were prepared as described elsewhere (Hiwasa and Sakiyama, 1996) and standardized by Bradford assay. 200 mg of each lysate sample was incubated with 2 mg of cyclin B1 M-20 antisera (Santa Cruz). Immunoprecipitates were analysed by 7.5% SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted for endogenous cyclin B1 using a 1 : 1000 dilution of cyclin B1 M-20 antisera (Santa Cruz). To detect phosphorylated cyclin B1, nitrocellulose membranes were stripped with stripping buffer (2% SDS, 62.5 mM Tris-HCl pH 6.8, 100 mM b-mercaptoethanol) for 30 min at 651C and then washed extensively with 0.05% TBS-Tween (TBS-T). Samples were then immunoblotted for phosphoserine cyclin B1 using a 1 : 1000 dilution of phosphoserine antisera (Zymed). Cell lysate samples from nuclear and cytoplasmic fractions were analysed by 10% SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted for endogenous lamin proteins with a 1 : 1000 dilution of lamin A/C 636 antisera (Santa Cruz).
Indirect immunofluorescence
At 2 days after transfection, NIH3T3 cells were fixed with 3% paraformaldehyde and permeabilized with blocking solution. Triple-label immunofluorescence was as follows: (i) endogenous Gli1 proteins were detected with a 1 : 250 dilution of Gli-1 N-16 antisera (Santa Cruz) and a 1 : 500 dilution of FITC-conjugated anti-goat antisera (Boehringer Mannheim);
(ii) endogenous phospho-histone H3 proteins were detected with a 1 : 200 dilution of phospho-H3 antisera (Upstate) and a 1 : 500 dilution of rhodamineconjugated anti-rabbit antisera (ICN-Cappel); and (iii) nuclei were stained with 50 ng/ml of Hoechst 33342 dye (Sigma). A total of 100 cells were counted per sample from three independent transfections, presented as the percentage of cells positive for nuclear Gli1 expression over the total number of cells counted (mean values7s.e.m.). Cells were scored positive for nuclear Gli1 expression if they demonstrated Gli1 predominantly nuclear.
